ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2021.76.12ymj-596Research ArticleМЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯMETHODS OF DIAGNOSIS AND TREATMENTОпределение фармакокинетических параметров изониазида с помощью высокоэффективной жидкостной хроматографии у пациентов с туберкулезом легкихDetermination of the pharmacokinetic parameters of isoniazid using high performance liquid chromatography in patients with pulmonary tuberculosisНиколаевВ. М.NikolaevV. M.

Николаев Вячеслав Михайлович – к.б.н., гл.н.с.-руковод. отдела

Nikolaev Vyacheslav Mikhailovich – Candidate of Biological Sciences, Head of the Department for the Study of Adaptation Mechanisms

6/3 Yaroslavsky str., Yakutsk, 677000, tel: +7(4112) 31-93-94

Nikolaev1126@mail.ruhttps://orcid.org/0000-0002-4811-7801КрасноваН. М.KrasnovaN. M.

Краснова Наталия Михайловна – к.м.н., доцент Медицинского института

Krasnova Natalia Mikhailovna – Candidate of Medical Sciences, Associate Professor of the Department "Hospital Therapy, Occupational Diseases and Clinical Pharmacology, Medical Institute

677000, Yakutsk, Belinsky 58 str., tel.: +7 (914) 109-40-22

krasnova14@mail.ruСофроноваС. И.SofronovaS. I.

Софронова Саргылана Ивановна – к.м.н., гл.н.с.-руковод. отдела

Sofronova Sargylana Ivanovna, Candidate of Medical Sciences, Head of the Scientific-organizational and Information-Publishing Department

6/3 Yaroslavsky str., Yakutsk, 677000, tel.: +7(4112) 31-93-94

sara2208@mail.ruПрокопьевЕ. С.ProkopyevE. S.

Прокопьев Егор Спиридонович – директор

г. Якутск

Prokopyev Egor Spiridonovich, Director

677015, Yakutsk, ul. Peter Alekseev, 93, tel.: +7 (4112) 39-03-30

npcftiz@gov14.ruhttps://orcid.org/0000-0002-9210-3407КравченкоА. Ф.KravchenkoA. F.

Кравченко Александр Федорович – д.м.н., зам. директора по мед. помощи в амбулаторных условиях

Kravchenko Aleksandr Fedorovich – Doctor of Medical Sciences, Deputy Director for Outpatient Medical Care

677015, Yakutsk, ul. Peter Alekseeva, 93, tel.: +7 (4112) 39-03-30

kravchenkoaf@tub.ykt.ruhttps://orcid.org/0000-0002-4496-3680СычевД. А.SychevD. A.

Сычев Дмитрий Алексеевич – д.м.н., проф., член-корр. РАН, проф. РАН, ректор

г. Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding member RAS, RAS professor, Rector

2/1 Barrikadnaya str., building 1, Moscow, 125993, tel.: +7 (495) 680-05-99

dmitrysychevrmapo@gmail.comЯкутский научный центр комплексных медицинских проблемРоссияYakut Scientific Center of Complex Medical ProblemsRussian FederationСВФУ им. М.К. АммосоваРоссияNorth-Eastern Federal University named after M.K. AmmosovRussian FederationНПЦ «Фтизиатрия» им. Е.Н. АндрееваРоссияScientific and Practical Center "Phthisiology" named after E.N. AndreevRussian FederationНПЦ «Фтизиатрия»РоссияScientific and Practical Center "Phthisiology"Russian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»РоссияRussian Medical Academy of Continuous Professional EducationRussian Federation202104052025045256Copyright © Николаев В.М., Краснова Н.М., Софронова С.И., Прокопьев Е.С., Кравченко А.Ф., Сычев Д.А., 20252025Николаев В.М., Краснова Н.М., Софронова С.И., Прокопьев Е.С., Кравченко А.Ф., Сычев Д.А.Nikolaev V.M., Krasnova N.M., Sofronova S.I., Prokopyev E.S., Kravchenko A.F., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/596

Методом высокоэффективной жидкостной хроматографии определена равновесная концентрация изониазида в плазме крови у пациентов с туберкулезом легких, проживающих на территории Республики Саха (Якутия). Подтверждена высокая индивидуальная вариабельность фармакокинетических параметров: максимальная равновесная концентрация препарата, площадь под фармакокинетической кривой, средняя стационарная концентрация препарата, степень колебания концентрации изониазида в плазме крови пациентов с туберкулезом. Индивидуальные различия фармакокинетических параметров изониазида указывают на необходимость проведения терапевтического лекарственного мониторинга при назначении изониазида.

The equilibrium plasma concentration of isoniazid in patients with pulmonary tuberculosis living in the Republic of Sakha (Yakutia) was determined by the method of high performance liquid chromatography. The high individual variability of pharmacokinetic parameters was confirmed : the maximum equilibrium concentration of the drug, the area under the pharmacokinetic curve, the average stationary concentration of the drug, the degree of fluctuation in the concentration of isoniazid in the blood plasma of patients with tuberculosis. Individual differences in the pharmacokinetic parameters of isoniazid indicate the need for therapeutic drug monitoring when prescribing isoniazid.

туберкулезфармакокинетикаравновесная концентрацияизониазидвысокоэффективная жидкостная хроматографияtuberculosispharmacokineticsequilibrium concentrationisoniazidhigh performance liquid chromatographyReferencesМорозова Т.Е. Фармакогенетические подходы к прогнозированию эффективности и безопасности фармакотерапии артериальной гипертензии [Электронный ресурс]: Лечащий врач / Т.Е. Морозова, Д.А. Сычев, Н.В. Ших. – М.: ООО «Издательство "Открытые системы"», 2016. №03. URL: http://www.rfbr.ru/pics/22394ref/file.pdf (Дата обращения 08.11.2021).Morozova T.E., Sychev D.A., Shikh N.V. Pharmacogenetic approaches to predicting the efficacy and safety of pharmacotherapy of arterial hypertension [Electronic resource]: Physician // Open Systems Publishing House LLC (Moscow). 2016. No. 03. URL: http://www.rfbr.ru/pics/22394ref/file.pdf (Date of treatment 11/08/2021)].Сергиенко В. И. Математическая статистика в клинических исследованиях / В.И. Сергиенко, И.Б. Бондарева. – М.: ГЭОТАР–МЕД, 2007.Sergienko VI, Bondareva IB Mathematical statistics in clinical trials; GEOTAR-MED, Moscow (2007).Сергиенко В. И. Прикладная фармакокинетика: основные положения и клиническое применение / В.И. Сергиенко, Р. Джеллифф, И.Б. Бондарева. – М.: РАМН, 2003.Sergienko V.I., Jelliff R., Bondareva I.B., Applied pharmacokinetics: basic provisions and clinical application; RAMS, Moscow (2003).Aït Moussa L, El Bouazzi O, Serragui S, Soussi Tanani D, Soulaymani A, Soulaymani R. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. Ther Adv Drug Saf. 2016;7(6):239-247. doi:10.1177/2042098616667704Aït Moussa L, El Bouazzi O, Serragui S, Soussi Tanani D, Soulaymani A, Soulaymani R. Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis. Ther Adv Drug Saf. 2016;7(6):239-247. doi:10.1177/2042098616667704Ali MH, Alrasheedy AA, Kibuule D, et al. Isoniazid acetylation phenotypes in the Sudanese population; findings and implications. J Clin Tuberc Other Mycobact Dis. 2019;17:100120. Published 2019 Sep 6. doi:10.1016/j.jctube.2019.100120Ali MH, Alrasheedy AA, Kibuule D, et al. Isoniazid acetylation phenotypes in the Sudanese population; findings and implications. J Clin Tuberc Other Mycobact Dis. 2019;17:100120. Published 2019 Sep 6. doi:10.1016/j.jctube.2019.100120Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update [published correction appears in Drugs. 2014 Jun;74(9):2061. Dosage error in article text]. Drugs. 2014;74(8):839-854. doi:10.1007/s40265-014-0222-8Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update [published correction appears in Drugs. 2014 Jun;74(9):2061. Dosage error in article text]. Drugs. 2014;74(8):839-854. doi:10.1007/s40265-014-0222-8Combrink M, Loots DT, du Preez I. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. Toxicol Lett. 2020;322:104-110. doi:10.1016/j.toxlet.2020.01.018Combrink M, Loots DT, du Preez I. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. Toxicol Lett. 2020;322:104-110. doi:10.1016/j.toxlet.2020.01.018Fernandes GFDS, Salgado HRN, Santos JLD. Isoniazid: A Review of Characteristics, Properties and Analytical Methods. Crit Rev Anal Chem. 2017;47(4):298-308. doi:10.1080/10408347.2017.1281098Fernandes GFDS, Salgado HRN, Santos JLD. Isoniazid: A Review of Characteristics, Properties and Analytical Methods. Crit Rev Anal Chem. 2017;47(4):298-308. doi:10.1080/10408347.2017.1281098Huerta-García AP, Medellín-Garibay SE, Ortiz-Álvarez A, et al. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. Int J Clin Pharm. 2020;42(4):1217-1226. doi:10.1007/s11096-020-01086-1Huerta-García AP, Medellín-Garibay SE, Ortiz-Álvarez A, et al. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. Int J Clin Pharm. 2020;42(4):1217-1226. doi:10.1007/s11096-020-01086-1Isoniazid. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; April 5, 2018.Isoniazid. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; April 5, 2018.Jung JA, Kim TE, Lee H, et al. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther. 2015;9:5433-5438. Published 2015 Sep 30. doi:10.2147/DDDT.S87131Jung JA, Kim TE, Lee H, et al. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther. 2015;9:5433-5438. Published 2015 Sep 30. doi:10.2147/DDDT.S87131Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. Expert Opin Drug Metab Toxicol. 2018;14(1):59-82. doi: 10.1080/17425255.2018.1416093Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. Expert Opin Drug Metab Toxicol. 2018;14(1):59-82. doi: 10.1080/17425255.2018.1416093O'Connor C, Brady MF. Isoniazid. In: Stat-Pearls. Treasure Island (FL): StatPearls Publishing; July 18, 2021.O'Connor C, Brady MF. Isoniazid. In: Stat-Pearls. Treasure Island (FL): StatPearls Publishing; July 18, 2021.Park JS, Lee JY, Lee YJ, et al. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother. 2015;60(1):92-98. Published 2015 Oct 12. doi:10.1128/AAC.00693-15Park JS, Lee JY, Lee YJ, et al. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome. Antimicrob Agents Chemother. 2015;60(1):92-98. Published 2015 Oct 12. doi:10.1128/AAC.00693-15Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464-1473. doi:10.1093/infdis/jit352Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464-1473. doi:10.1093/infdis/jit352Ramachandran G, Agibothu Kupparam HK, Vedhachalam C, et al. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India. Antimicrob Agents Chemother. 2017;61(5):e02464-16. Published 2017 Apr 24. doi:10.1128/AAC.02464-16Ramachandran G, Agibothu Kupparam HK, Vedhachalam C, et al. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India. Antimicrob Agents Chemother. 2017;61(5):e02464-16. Published 2017 Apr 24. doi:10.1128/AAC.02464-16

The authors declare that there are no conflicts of interest present.